Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis

Abstract

Objectives The multi-biomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in rheumatoid arthritis (RA). Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA. Methods We performed a systematic literature search in five medical databases: MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, Scopus, and Web of Science, from inception to 13 October 2021. Original articles reporting on the performance of the MBDA score’s correlation with conventional disease activity measures, or the predictive and the discriminative value of the MBDA score for radiographic progression, therapy response, remission, and relapse were included. Results Our systematic search provided a total of 1190 records. After selection and citation searches, we identified 32 eligible studies. We recorded moderate correlations between MBDA score and conventional DAMs at baseline (COR = 0.45, CI: 0.28–0.59; I2 = 71.0% for DAS28 CRP and COR = 0.55, CI: 0.19–0.78; I2 = 0.0% for DAS28-ESR) and at follow-up (COR = 0.44, CI: 0.28–0.57; I2 = 70.0% for DAS28 CRP), and found that the odds of radiographic progression were significantly higher for patients with a high baseline MBDA score (>44) than for patients with a low baseline MBDA score (<30) (OR = 1.03, CI: 1.02–1.05; I2 = 10.0%). Conclusion MBDA score might be used as an objective disease activity marker. In addition, it is also a reliable prognostic marker of radiographic progression.

Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care

“…The Multi-Biomarker Disease Activity (MBDA) score holds significant value in the care of RA patients, serving as a valuable tool for both monitoring disease activity and predicting radiological progression [ 181 ]. Nevertheless, further research is required to more effectively assess the utility of the MBDA score and explore the potential role of individual biomarkers in monitoring disease activity, especially in the context of cardiovascular diseases such as stroke in association with RA.…”

The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins

“…This scoring system offers an objective method for monitoring RA disease activity, facilitating the creation of personalized treatment plans in line with contemporary medical practices. Moreover, the MBDA score has been shown to predict radiographic progression, further demonstrating its utility in disease management and treatment optimization (for a review on the topic, see [ 103 ]. Despite the availability of various proteomic methods for analyzing these panels, their adoption in clinical settings has been slow.…”

Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines

“…Table 3 shows some of the risk factors and established laboratory findings related to RA for which the potential study population could be screened. In addition to age, gender, and smoking status, the patient’s HLA alleles, and RA-specific laboratory parameters ( 85 – 87 ) can be reviewed, keeping in mind that RA is a heterogeneous disease. Unfortunately, the field of RA-related biomarker tests has not advanced as fast as desired in order to allow identification of the best biomarkers to focus on at this stage of product development.…”

“…Unfortunately, the field of RA-related biomarker tests has not advanced as fast as desired in order to allow identification of the best biomarkers to focus on at this stage of product development. For further insights, the reader is referred to the description of a RA activity biomarker test (MBNA Vectra®, now provided by LabCorp) ( 85 – 87 ) and a RA genetics review ( 88 ).…”